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Abstract 
 
Wheat lignans are phenylpropane dimers linked by β-β bonds with a 1, 4-diarylbutane 
structure.   They are biosynthesized in the cell cytoplasm through action of enzymes of 
the phenylpropanoid pathway. Pinoresinol lariciresinol reductase (PLR) catalyzes the 
final steps of biosynthesis of wheat lignans. In epidemiological and clinical 
investigations, studies show that high plasma lignan amounts correlate with reduced risks 
of breast, colon, and prostate cancers. However, in some of the studies, the results are not 
consistent. More consistent results are observed when animal and cell culture models are 
used. Our previous studies in the Wang lab demonstrated that treatment of human colon 
cancer cells, SW480 with lignans results in a dose and time dependent inhibition of 
cancer cell growth.  In the first paper, we investigated direct experimental cancer 
preventative characteristics of a wheat lignan, secoisolariciresinol diglucoside (SDG) vs. 
its metabolite enterolactone in human colon cancer SW480 cells. Treatment of cancer 
cells with 0-40 µM SDG or enterolactone resulted into inhibition of cancer cell growth as 
observed by reduction of cell numbers. The reduction appeared related to induction of S-
phase cell cycle arrest rather than cytotoxic effect. Further analysis revealed that SDG 
was more stable in cell culture medium than enterolactone. HPLC-MS/ESI showed that 
enterolactone is the principle metabolite in cancer cells but undetectable SDG or its 
metabolites were in the cells treated with SDG. In the second paper, we investigated over 
expression of the PLR gene and enhancement of lignan levels in transgenic wheat. We 
transformed wheat cultivars (‘Bobwhite’, ‘Madison’, and ‘Fielder’ respectively) with the 
Forsythia intermedia PLR gene under the regulatory control of the maize ubiquitin 
promoter. Of the total 217 transgenic wheat lines, we successfully obtained 7 
transformants with the inserted ubiquitin PLR gene as screened by PCR. Real-time PCR 
further indicated 109-117% PLR over expression over the transgenic control in 3 
transformants of the 7 at T0 generation. In addition, the levels of SDG, as determined by 
HPLC was found to be significantly elevated in one of the 3 positive transgenic plants. 
To the best of our knowledge, this is the first study reported that genetically engineered 
wheat with over expressed PLR enzyme enhancing phytochemical lignan has been 
successfully achieved. 
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consistent. More consistent results are observed when animal and cell culture models are 
used. Our previous studies in the Wang lab demonstrated that treatment of human colon 
cancer cells, SW480 with lignans results in a dose and time dependent inhibition of 
cancer cell growth.  In the first paper, we investigated direct experimental cancer 
preventative characteristics of a wheat lignan, secoisolariciresinol diglucoside (SDG) vs. 
its metabolite enterolactone in human colon cancer SW480 cells. Treatment of cancer 
cells with 0-40 µM SDG or enterolactone resulted into inhibition of cancer cell growth as 
observed by reduction of cell numbers. The reduction appeared related to induction of S-
phase cell cycle arrest rather than cytotoxic effect. Further analysis revealed that SDG 
was more stable in cell culture medium than enterolactone. HPLC-MS/ESI showed that 
enterolactone is the principle metabolite in cancer cells but undetectable SDG or its 
metabolites were in the cells treated with SDG. In the second paper, we investigated over 
expression of the PLR gene and enhancement of lignan levels in transgenic wheat. We 
transformed wheat cultivars (‘Bobwhite’, ‘Madison’, and ‘Fielder’ respectively) with the 
Forsythia intermedia PLR gene under the regulatory control of the maize ubiquitin 
promoter. Of the total 217 transgenic wheat lines, we successfully obtained 7 
transformants with the inserted ubiquitin PLR gene as screened by PCR. Real-time PCR 
further indicated 109-117% PLR over expression over the transgenic control in 3 
transformants of the 7 at T0 generation. In addition, the levels of SDG, as determined by 
HPLC was found to be significantly elevated in one of the 3 positive transgenic plants. 
To the best of our knowledge, this is the first study reported that genetically engineered 
wheat with over expressed PLR enzyme enhancing phytochemical lignan has been 
successfully achieved. 
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CHAPTER 1 - WHEAT LIGNANS AND CANCER PREVENTION-
LITERATURE REVIEW 
 
 
 
 
 
 1
Wheat Lignans and Cancer Prevention 
Summary 
Wheat lignans have phenylpropane dimers linked by β-β bonds with a 1,4-diarylbutane 
structure. They occur in significant amounts mainly as glycosides in aleurone layer of wheat 
kernels after biosynthesis in the cell cytoplasm through the phenylpropanoid pathway. In the 
phenylpropanoid pathway, wheat lignans are synthesized from simple phenyl derivatives such as 
corniferyl alcohols. The initial and final steps in this pathway involves deamination of 
phenylalanine catalyzed by phenylalanine ammonia lyase and reduction of pinoresinol to 
secoisolaciresinol by pinoresinol lariciresinol reductase respectively. On consumption, lignans 
are metabolized in the colon into enterolactone and enterodiol by the bacterial fermentation 
process. Enterolactone and enterodiol are important because they can be used as biomarkers in 
epidemiological studies. Epidemiological studies suggest that high circulating levels of lignan 
metabolites are correlated with reduced risks of chronic diseases such as cancer and 
cardiovascular disease. The same observation has also been observed in animal and cell culture 
models. For example, investigations in the mice induced to develop mammary carcinogenesis 
and treated with a wheat lignan at 0.01% (w/w) in diet showed reduced mammary carcinogenesis 
related biomarkers. Some of the mechanisms that are suggested for wheat lignan health 
protecting roles include anti-oxidant, anti-estrogenic, anti-proliferation, cell cycle induction, and 
apoptosis.   
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Biosynthesis of lignans 
Very little information is available about the wheat phenylpropanoid pathway that occurs 
in the cell cytoplasm. However, earlier work on the contention of phenylpropanoid pathway has 
suggested the endoplasmic reticulum as the main organelle for this pathway (1-3).  Enzymes of 
interest, phenylalanine ammonia lyase (E.C. 4.3.1.5) and pinoresinol lariciresinol reductase are 
among two of the enzymes involved in this pathway that catalyze initial and final steps 
respectively. Phenylalanine ammonia lyase catalyses the first step of the phenylpropanoid 
pathway involving deamination of phenylalanine to produce ammonia ion as a by-product while 
pinoresinol lariciresinol reductase catalyses the sequential reductive fission of pinoresinol to 
lariciresinol and then secoisolaciresinol. Lignans are biosynthesized to form monomeric or 
oligomeric lignans that are packaged as glycosides before release into the wheat aleurone layer 
during the seed development stage such as secoisolariciresinol diglucoside (SDG) (4). 
Monomeric lignans have been found in wheat, in tea (5) while an oligomeric lignan has been 
shown in flax (6). Our focus is primarily on the prominent monomeric lignan, SDG present in 
wheat. 
Other monomeric wheat lignans in the phenylpropanoid pathway (Fig. 1) include 
pinoresinol, lariciresinol, and secoisolaciresinol. The sequential reductive fission of pinoresinol 
to lariciresinol and then to secoisolaciresinol is a key regulatory point in this pathway and is 
catalyzed by pinoresinol lariciresinol reductase as has shown in woody plants (7, 8) and in flax 
seeds (9). Very little information on the enzymatic actions of  pinoresinol lariciresinol reductase. 
In the last decade, Norman and his colleagues at Washington State University have managed to 
isolate the pinoresinol lariciresinol reductase enzyme from Forsthysia intermedia (10, 11). Their 
work and that of others on identification of the DNA sequence of pinoresinol lariciresinol 
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reductase enabled us to isolate the very first partial sequence of the wheat pinoresinol 
lariciresinol reductase gene (Fig. 2) using primers designed based on the Forsthysia intermedia 
cDNA (see appendix B). Wheat pinoresinol lariciresinol reductase shares 50% sequence similar 
with the Forsthysia pinoresinol reductase gene. To the best of our knowledge, this is the first 
time the partial sequence of the wheat PLR sequence has been shown.  
 4
  
 
Figure 1:1 Phenylpropanoid pathway for lignan biosynthesis showing last stage lignan 
formation catalyzed by pinoresinol lariciresinol reductase 
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Figure 1:2 Partial sequence (~50% length of forsthysia 1.2 kb PLR sequence) of the 
wheat pinoresinol lariciresinol reductase gene 
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Bioavailability of lignans 
The bioavailability of wheat lignans refers to the amount of wheat lignans that are 
absorbed into the blood stream after passage through the mammalian gut system (12). 
Consumption of wheat lignans and subsequent exposure to enzymatic and bacterial activity in 
the mouth, stomach, intestines, colon and cecal generates lignan metabolites, enterodiol and 
enterolactone. Bacterial activity in the colon results into fermentation of lignans into enterodiol, 
which is subsequently oxidized into enterolactone. Once formed, lignan metabolites are absorbed 
into the blood stream mainly through a passive mechanism. Excess unabsorbed lignan 
metabolites are excreted in urine and fecal matter (13). 
 Commercial foods rich in wheat lignans include shredded wheat cereal, toasted 
wheat bran flasks, and whole wheat bread (14). When these foods are consumed, the chewing 
action of the mouth physically breaks down wheat lignans into small swollenable particles. In 
addition to that, the first step of metabolism may involve removal of the attached sugars in the 
lignan glycosides; a reaction catalyzed by glycosidase. Glycosidase activities can occur in the 
food itself (endogenous or added during processing) or in the cells of the gastrointestinal mucosa 
or can be secreted by the colon micro flora (15). Colon micro floras are also important in wheat 
lignan fermentation process that occurs in the distal end of the digestive system.  
Many factors are suggested to affect the overall efficiency of the bacterial fermentation 
for formation of lignan metabolites, enterolactone and enterodiol. Most important of all these 
factors is the food matrix in which the lignans are bound. Foods which are milled and finely 
crushed will provide a higher mammalian lignan source than others such as wheat bran or ground 
flax seeds (16). Besides milling, extrusion processes may be important in increasing accessibility 
of wheat lignans to the fermentation process. In addition, surgical procedures such as removal of 
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the distal section of the digestive gut such as in colon ileostomy may reduce overall 
enterolactone and enterodiol formation as seen with a rye diet (17).  
Pharmacokinetics relates to the rate of availability and elimination of mammalian lignans 
from different organs within the body. A recent study on the availability of enterolactone and 
enterodiol after a dietary rich lignan meal (18) and after ingestion of purified SDG alone (19). In 
the later study, twenty healthy volunteers on a dose of purified SDG (1.31 μmol/kg body weight) 
show maximum blood plasma levels of enterolactone and enterodiol at 19.7 +/- 6.2 and 14.8 +/- 
5.1 hrs respectively post ingestion. This indicates that enterodiol circulates faster than 
enterolactone. In their discussion, the authors suggest that both enterolactone and enterodiol are 
distributed through way of first order of kinetics. In addition, uptake of enterolactone and 
enterodiol has also been analyzed in vitro using different human epithelial cells (20). Jansen et al 
shows that conjugation and excretion of enterolactone and enterodiol in HT29, CCD841CoTr 
and CaCo-2 cells is complete after 8 hrs except for enterodiol in Caco-2 cells (20).  
After intake, enterolactone and enterodiol are excreted in urine as glucuronates (73-94%) 
or sulfate conjugates (2-10%), as free phenols in feacal matter (21).  In animal models, the 
concentration of enterodiol and enterolactone excreted is dependent on the percentage amount 
consumed. For a diet supplemented with 0% -5% flax seeds, metabolite excretion is observed to 
increase exponentially and before it plateaus off at 5-10% (22).  
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 Figure 1:3 Lignan metabolism showing the fate of lignans through the digestive gut and its 
major metabolites, enterolactone and enterodiol 
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Lignans and cancer prevention studies 
Many studies have established that there exists an inverse relationship between lignan 
consumption and reduced cancer risks. Lignan plasma amounts are directly correlated with 
reduced cancer risk as shown in some population studies and proved in animal and cell culture 
models 
Epidemiological and clinical studies 
Although conflicting data does exist, many epidemiological studies suggest an inverse 
relationship between wheat lignan consumption and various cancer risks including breast, colon, 
prostate and other cancers.  
The earliest work on association between wheat lignan intake and the risk of breast 
cancer was done by Adlercreutz and his colleagues (23). In that landmark publication, the 
authors found that lignan excretion high in vegetarian Asian women is accompanied by a low 
breast cancer risk while in omnivorous Boston women, lignan excretion was low accompanied 
with a high breast cancer risk (23). Today, at least 183 publications discuss the epidemiological 
results between lignan intake and breast cancer, a few with conflicting results (24). In a recent 
review article, the authors suggested that the inverse relationship between lignan consumption 
and breast cancer are more consistent in case-control studies vs. prospective studies, in pre-
menopausal women vs. menopausal women, and in analysis of enterolactone vs. enterodiol (25). 
We recently published a book chapter (in press) where we emphasize essentially the same 
conclusions and add that the conflicting data are in part due to inadequate databases used in 
dietary lignan estimation as suggested by others (26). We further add here that estrogen receptor 
status and diet-gene interactions are essential in the analysis of epidemiological intervention data 
of dietary lignans in breast cancer (27). Perhaps, that is why Touillard and colleagues (2007) did 
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observe an inverse relationship between dietary lignan intake (< 1395 µg/day), enterolignan 
exposure and the risk of invasive breast cancer when they considered breast cancers that were 
estrogen and progesterone receptor positive for women who were post menopause (28). 
In colon cancer epidemiological studies, the relationship between lignan intake and colon 
cancer is also summarized by a recent publication conducted in Netherlands that demonstrates 
that a substantial reduction of colorectal adenoma risk is associated with a high plasma level of 
lignan metabolites (29).  In a Ontario based colon cancer population case control study involving 
1095 cases and 1890 control subjects, the authors suggest that dietary lignan intake is associated 
with a significant reduction in colorectal cancer risk [OR (T3 vs. T1) = 0.73; 95% CI: 0.56, 
0.94]. They did not observe any evaluated interactions between polymorphic genes that encode 
enzymes possibly involved in metabolism of phytoestrogens (CYPs, catechol O-methyl 
transferase, GSTs, and UGTs) and the risk of colon cancer (30). 
In prostate cancer epidemiological studies, Arts and Hollman’s review (31) suggest that 
the inverse relationship between lignan intake and prostate cancers is consistent when case-
control studies are used and none when using prospective and nest case control studies. The same 
view is held by other authors (32, 33). In one of the few conflicting case control studies, a 2006 
Swedish population-based case control study, the authors show conflicting results for a 
questionnaire-data for 1,499 prostate cases vs. 1,130 controls. They suggest no association 
between dietary intake of total or individual lignans and risk of prostate cancer. However, on 
further analysis, intermediate serum levels of enterolactone were associated with a decreased risk 
of prostate cancer (34). 
In other cancer related epidemiological studies; women show a 50% (OR, 0.50; 95% Cl, 
0.31-0.68; P=.04 for interaction) reduction in lung cancer risk when both hormone therapy use 
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and intake of enterolactone and enterodiol are analyzed together [ongoing US- base case control 
study (35)]. 
 In the University of Texas M.D. Anderson study, no association is suggested between 
dietary lignan intake and reduction of testicular cancer in young men (36). 
In conclusion, across all the cancers, the inverse relationship between wheat lignan 
consumption and cancer risk reduction are more observable in case control studies than in 
prospective cohort studies (25, 37) especially as seen in breast cancers.  Perhaps, future studies 
should employ improved exposure assessment and multiple sampling techniques to ascertain 
positive associations. Also, the use of other biomarkers such as lignan antioxidant activity and 
sex hormone binding protein levels instead lignan metabolite levels for determination of 
associated cancer risks is suggested (38, 39).   
Experimental animal and cell cultures studies 
Many studies involving cancer inducible animal models and cell culture models test the 
potential benefits of lignans as anti-cancer agents by using either purified lignan preparations or 
foods rich in lignans. Unlike epidemiological studies, more consistent results are evident in 
experimental animal and cell culture studies. A summary of some of the important studies is 
shown below; 
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 Table 1.1 Lignan cancer prevention studies in animal models 
Source Causative agent and/ 
animal model 
Effects on Cancer Ref 
10% flax (or equivalent SDG) NMU induced mammary 
tumor genesis in F344 rats 
   number and size of   
   mammary  adenoma  
    carcinomas                    
40 
10 mg/kg enterolactone DMBA induced mammary 
tumorigenesis 
    
    tumor number 
41 
5% or 10% flaxmeal or  
SDG equivalent 
AOM induced Sprague-
Dawley rats 
   number of crypts, foci   
    and cell proliferation 
42 
10% flaxseed or SDG Nude mice injected with 
MDA-MB-435  
    lung and lymph  
    metastases 
43 
0.02% secoisolariciresinol/ 
Matairesinol 
Min Mice      no effect 44 
73-293 µmol/kg SDG or  
2.5-10% flax seeds 
B16BL6 murine melanoma 
cells in C57BL/6 mice 
    tumor number and size 45 
0.01% SDG in diet Azoxymethane induced F344 
rats 
    abberant cryt foci 26 
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In the above studies, carcinogenesis or tumor markers in animal models is induced with 
either azoxymethane or N-nitroso N-methylurea (NMU) or 7, 12-dimethylbenz (α) anthracene 
(DBMA) (41-44, 47) treated along with lignan or lignan enriched diets. In one case, spontanous 
carcinogenesis animal model, Apcmin (mutated adenomatous polyposis coli gene) (45) were 
used. In two cases, human breast cancer cell lines or melanoma cancer cell lines xenografted into 
the animal model caused cancers (44, 46). In almost all animal models, lignan 
supplementation/treatment is started before induction of the carcinogenesis except in a few cases, 
where it was after carcinomas had been established.  Wheat lignan or SDG equivalent diets (that 
is purified SDG of  73, 147 and 293 μ mol/ kg body equivalent to flaxseed at 2.5, 5 and 10% 
w/w) was the most common lignan diet used except two studies that used enterolactone injected 
intravenously (42) and secoisolaciresinol and matairesinol (44).  
The results indicate that wheat lignans are chemo-preventative against initial stages of 
carcinogenesis as seen by reduction in number of early carcinogenesis related markers, such as 
number of ACF (aberrant crypt foci), size and number of adenoma, size and number of tumors 
and number of metastases.  
Unlike the animal model experiments, the cell culture studies on human colon (47 – 49) 
prostate (50) and breast cancer cell lines (51) mostly use enterolactone and enterodiol. Our study 
suggested enterolactone inhibited a human colon cancer cell line, SW480 in a time and dose 
dependent manner (48). The effect may be additive when both enterolactone and enterodiol are 
combined (49).  Enterolactone is also shown to induce apoptosis and inhibit growth in human 
colon cancer cell line, colo-201 (49). In this study, the expression of apoptosis suppressor protein 
and proliferation related PCNA protein is down regulated while apoptosis enhancing protein is 
up-regulated (49). In four other human colon tumor cell lines; LS174T, CaCo-2, HCT-15 and T-
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84, enterolactone and enterodiol at 100 µM concentration reduced cell proliferation (39).  In 
human breast cancer cell line (MCF-7), enterolactone at 10 nM significantly inhibited the growth 
of cells (51). At a lower dose (0.5-2 nM), the effect was stimulatory for cell proliferation; the 
dose amount used is the same as the levels of estrogen hormone estradiol circulating under 
normal conditions (1 nM). This and other studies suggested that enterolactone is agonist towards 
estradiol receptors in stimulated MCF-7 breast cancer cells at a low dose but antagonist at higher 
doses, hence indicating a possible mechanism by which it affects growth of estrogen sensitive 
cells (51). In prostate cancer cell lines (PC-3, DU-145, LNCAP), 10-100 μM enterolactone and 
enterodiol significantly inhibit growth of all cell lines (40). In this study, enterolactone (IC 50 of 
57 μM) is more potent than enterodiol (IC 50 of 100 μM) (50). 
Therefore, in conclusion, growth inhibitory effects in the cancer cell lines can be 
explained by several mechanisms; such as anti-oxidant, estrogenic and anti-estrogenic 
mechanisms among others. 
Plausible mechanisms of lignans in cancer prevention 
Many studies suggest that wheat lignans are chemo preventative agents (52) towards 
chronic diseases such as cancer through anti-oxidant, anti-estrogenic and other potential 
mechanisms.  
Anti-oxidant activity 
Wheat lignans are chemo-preventative agents that with high anti-oxidant activity (53). 
Reports ascertain that wheat lignans in physiologically important doses are 3-4 times more 
potent than vitamin E (54). SDG and its metabolites enterodiol and enterolactone have been 
reported to have scavenging ability towards free radicals (55, 56). However, comparison of anti-
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oxidant activity between SDG and its metabolites, enterolactone and enterodiol indicated that 
SDG may have (58).  It is further suggested that lignan’s free radical scavenging ability may 
eliminate potential carcinogens such as reactive oxygen species through participation in phase 1 
reactions. Free radical scavenging mechanism may explain for the plant lignans anti-oxidant role 
in 1) reduction of risks associated with coronary and cardiovascular diseases as in the Zupter 
elderly study (58) and as in Arts review (31), 2) reduction of lipoprotein intake into cells in 
atherogenic lesions.  
A genomic response will result when leaking reactive oxygen species from the 
mitochondria stimulates redox sensor kinases that in turn activate transcription factors through 
the Nrf2 pathway (59). Through the Nrf2 pathway, active transcription of phase 2 metabolism 
enzymes will result and hence further consolidate the detoxification process. Hence, wheat 
lignans can essentially eliminate all these downstream pathways through elimination of reactive 
oxygen species.  Infact, previous work of the Wang lab found that enterolactone was capable of 
inducing detoxification enzyme activity (60) most likely related to phase 2 metabolism.  
Anti-estrogenic activity 
Lignans as phytoestrogens act through estrogen receptor-mediated mechanisms.  
Structural similarity to estrogen receptors allows mammalian lignans to act as estrogenic 
antagonists competing with beta-oestradiol in the estrogen receptor complex.  The levels of 
severity of a estrogen dependent cancer such as breast cancer is lower with high circulating 
levels of lignans and the reverse is also true. Inhibition of aromatase and 17 beta-hydrosyteroid 
dehydrogenase (important enzymes in estrogen synthesis) after a lignan ingestion, are suggested 
as strong evidence for this role (61). In relation to this, is the production of presenilin 2 in MCF-
7 breast cancer cell lines elicited by mammalian lignan, enterolactone.  Presenilin 2 production is 
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directly associated with inhibition of cellular proliferation as seen in breast cancer cells. A 
biphasic growth effect involving induction of cell proliferation at doses <10 µM enterolactone, 
and inhibition of the same at >10 µM has been observed in vitro (62).  
 In addition to this, lignans as phytoestrogens have been suggested to lower 
cholesterol through increased low density lipo-protein receptor activity (63). Wu et al (2006) also 
suggested that lignans ingestion from sesame may improve sex hormones through increased 
levels of sex hormone binding globulin in postmenopausal women (64). 
 However, estrogenic activity of lignans have been correlated with causing adverse 
effects in animals as reviewed by Rickard and Thompson (65) with some contradictions. Ward et 
al (2001) exposed flaxseed or SDG in diets of dams and observed no alteration of reproductive 
indices in male and female offsprings (66). In humans, Mitchell et al (2001) concluded that 
phytoestrogen dose had no effect in male semen quality (67).  
Other potential Mechanisms 
A recent study done in our lab showed that enterolactone, a mammalian phytoestrogen, 
causes a dose and time dependent inhibitory effect on the growth of SW480 cells due to S-phase 
cell cycle arrest (48). Other reports have also indicated a similar trend effect of lignans on cell 
cycle control points, and the apoptosis pathway. In the cell cycle, key control points involving 
tumor suppressor protein; the p53 protein, p21, p15 among others have been suggested to be 
involved in the growth inhibitory effect of lignans. Enterodiol is known to induce apoptotic cell 
death in MCF-7 tumors by increased expression of p21 protein levels and decrease of Bcl-2 
levels (apoptosis suppressing protein), cyclin D1, and Rb protein expression (68). Rb protein is 
important in progression of cells into S-phase. In another study, secoisolariciresinol 
administration to D-galactosamine/lipopolysaccharide (LPS)-induced hepatic injury in mice 
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resulted in direct inhibition of apoptosis mediated by tumor necrosis factor alpha (TNF-alpha) 
(69). 
Supplementation of min mice with a 10% rye (colon rye fermentation produces 
enterolactone) is significantly associated with normalized beta- catenin levels thus reducing the 
associated cell neoplasia in these min mice (70). In a study involving the TMCH mice (mice in 
which neoplasia is induced by Celiobacter rodentium) increased nuclear beta-catenin expression 
was recorded by both biochemical and histological approaches, accompanied by increases of 
cyclin-D1 and c-myc protein expression. When these mice were treated with lignans, levels of 
beta-catenin were normalized (71) resulting into regression of intestinal tumors.  
 Lignans also block TPA-induced phosphorylation of extracellular signal-regulated 
kinases (ERK) and UVB-induced phosphorylation of ERKs and JUN kinases via inhibition of 
AP-1 and NF-B transcriptional factors (72). Proto-oncoprotein c-fos, which constitutes part of 
the AP-1 transcription factor, is stated to be regulated by mammalian lignans in MDA-MB-468 
breast cancer cells. 
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Abstract 
Our previous study demonstrated that lignan metabolites, enterolactone and enterodiol, 
inhibited colonic cancer cell growth by inducing S-phase cell cycle arrest and apoptosis. 
However, the lignan present in our diet is glucoside precursors such as secoisolariciresinol 
diglucoside (SDG). This study is thus focused on the cancer preventative impact of SDG in 
human colonic SW480 cancer cells. Treatment with SDG at 0-40 µM resulted into a dose and 
time dependent decrease in cell numbers which was comparable to enterolactone. The cell 
growth inhibition by SDG seemed not mediated by cytotoxicity, but induced cell cycle arrest at 
S-phase. Furthermore, HPLC analysis indicated SDG in medium for 48 hrs was much more 
stable than enterolactone (95% stability for SDG vs. 57% for enterolactone). When the cells were 
treated by enterolactone at 40 µM for 48 hrs, the intracellular levels of enterolactone detectable 
was 8.3 x 10-8 nmol/cell. However, the intracellular levels of SDG or its known metabolites as 
measured by HPLC-MS/ESI were undetectable. Taken together, these findings provide novel 
characteristics of dietary lignan on colonic cancer cell growth. The stability and intracellular 
level analysis may enhance our understanding of bioavailability of dietary lignans for cancer 
preventation. 
Introduction 
Potential cancer preventive effects of precursor lignan, secoisolariciresinol diglucoside 
(SDG) have been suggested to be mediated through its metabolites, enterolactone and enterodiol 
(1-3) or even its aglycone, secoisolariciresinol (4, 5). Enterolactone and enterodiol are formed 
anaerobically after the bacterial colon fermentation process (6) of SDG.  Specialized bacterial 
strains, Peptostreptococcus sp. SDG-1 and Eubacterium sp. SDG-2 convert SDG into enterodiol 
(7) which may be oxidized to enterolactone. Besides the bacterial fermentation process, 
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enterolactone and enterodiol can also be formed by other cell types and organelles. A recent 
study showed that liver microsomes can generate lignan metabolites from other lignans, 
secoisolariciresinol and matairesinol (8). 
Many studies associate diet supplementation of SDG with cancer preventive properties in 
animal models. Our recent study showed that SDG levels in wheat bran was correlated to anti-
tumor activities in four wheat cultivars (9). Others also found that SDG at 0.01% significantly 
reduced azoxymethane-induced formation of abberant crypt foci (ACF) in mice (10). In addition, 
experimental animal studies show that dietary supplementation with 73-293 µmol/kg SDG 
inhibits experimental metastasis of B16BL6 murine melanoma cells in C57BL/6 mice (11).   
Anti-estrogenic activity of lignans has been suggested as a potential mechanism of anti-
cancer potential of lignans in especially estrogen dependent cancers (12). Structure similarity to 
estrogens allows lignans such as SDG to bind with the β-estrogen receptor and therefore inhibit 
17 β-estradiol activity as seen with decreased aromatase activity in studies involving lignan 
supplemented diets (13-15). Other potential mechanisms by which lignans are cancer preventive 
are discussed in current review (16). Important among suggested mechanisms, is the inhibitory 
effect of lignans on DNA synthesis (17). Inhibition of DNA synthesis may cause programmed 
cell death or apoptosis (18). 
In this study, we investigated direct cancer preventive characteristics of SDG in human 
colon cancer cells, SW480. The effect of SDG on inhibition of cancer cell growth was studied 
through cell cultures. Through chromatographic techniques, SDG was also investigated for 
medium stability compared to enterolactone. Finally, HPLC- MS/ESI was used to find out 
whether SDG or enterolactone were taken up intracellularly into human cancer cells treated with 
lignans hence their bioavailability for cancer preventive effects. 
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Materials and methods 
Cell culture and treatment 
The human colon cancer cells, SW480, were purchased from the American Type Culture 
Collection (Rockville, MD) and cultured in Dulbecco’s Modified Eagle Media supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis MO). 
The cells were cultured in either 6-well plates or 200 ml volumetric flasks at 37 0C in 5% CO2  
until 60-80% confluence. At this confluence, cells were treated with SDG and enterolactone, at 
0-40 µM for 24 and 48 hrs, at which time the cells had reached < 100% confluence. SDG (99% 
purity) was purchased from ChromaDex (Irvine, CA) while enterolactone was purchased from 
either Sigma-Aldrich (St Louis, Mo) or ChromaDex. The lignans were dissolved in DMSO and 
mixed with fresh medium to achieve the final concentration of DMSO at 0.2%, a concentration 
that did not alter cell growth or cell cycle measurements compared with the DMSO-free media. 
After treatment cells were detached and counted by hemacytometer as our previously reported 
(9). 
Cytotoxicity Assay 
The cell viability was measured in adherent cells by trypan blue staining. The viable cell 
numbers in treated cells were compared with that in vehicle controls. 
Cell cycle analysis 
Cell cycle analysis was done as previously described (9). Briefly, cells were fixed in 
ethanol, centrifuged and the pellet resuspended in phosphate buffer saline solution, pH 7.4, 
containing 20 g/L propidium iodide and 5000 U/L of RNase (Promega) at 37 0C for 30 mins. 
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DNA flow cytometric analysis (FACSCaliber, Becton Dickinson, Newyork, NJ) was performed 
with an excitation at 488 nm and an emission at 630 nm. 
HPLC quantification of SDG and enterolactone in cell culture medium 
HPLC-UV quantification of SDG and enterolactone was done according to previous 
methods (1, 24) with slight modification. Generally, cell culture medium containing remaining 
lignans was separated from cancer cells that had been treated with 0-40 µM SDG or 
enterolactone by centrifugation at 1000 X g for 10 minutes.  SDG and enterolactone were 
separated by HPLC chromatography on a C18 column (5 µm, 250 X 4.6 mm, Alltech), eluted 
with a 5% acetonitrile in pH 2.8, 0.01 mM phosphate buffer (solvent A) over 100% acetonitrile 
(solvent B) at a flow rate of 1 mL/ml. A gradient run of 0-10 minutes, 100% solvent A, 10-30 
minutes, 0-100% solvent B and finally 30-40 minutes, 100% solvent B was determined as 
optimum.  Peaks were detected by monitoring absorbance at 283nm. The enterolactone and SDG 
peak was identified according to both retention time and spectrum by comparison with a standard 
commercial SDG and enterolactone. A linear HPLC calibration curve for both lignans were 
obtained for the concentrations 0-100 µM.  
HPLC analysis of intracellular extracts of cancer cells treated with SDG and 
enterolactone 
SW480 cells treated with 40 µM SDG or enterolactone for 48 hrs were harvested by 
detaching with trypsin-EDTA as previously described (9) and centrifuged at 1000 X g for 10 
minutes. The supernatant was discarded, and the pellet was washed with 0.01 M phosphate 
buffer saline solution, pH 7.4. The collected cells were then re-suspended in washing buffer, and 
sonicated under an ice bucket, followed by three 1:1 diethyl ether extractions. The upper organic 
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phase containing the lignans was obtained and evaporated to dryness by passing a stream of 
nitrogen gas through it. The resulting residue was dissolved in 100% methanol and subjected to 
HPLC using the method described above.  
Mass spectrometry analysis of intracellular extracts of cancer cells treated with SDG 
and enterolactone  
SW480 cells treated with 40 µM SDG or enterolactone for 48 hr were harvested by 
detaching with trypsin-EDTA as previously described (9) and centrifuged at 1000 X g for 10 
minutes. The supernatant was discarded and the pellet washed and re-suspended in 0.01 M 
phosphate buffer saline solution, pH 7.4.  The resulting solution was homogenized under an ice 
bucket followed by three 1:1 diethyl ether extractions. The upper organic phase containing the 
lignans was evaporated to dryness in a water bath set at 350C under high pressure conditions. 
The residue remaining at the bottom of the flask was re-dissolved in 100% methanol and ultra-
centrifuged at 40,000 X g for 30 minutes. HPLC-MS/ESI analysis was performed with a 
Finnigan LCQ Deca XP mass spectrometer (Thermo Finnigan, Dreieich, Germany) coupled to an 
Agilent (Agilent, Waldbronn, Germany) 1100 series HPLC system. Separations were achieved 
with a synergi (Berlin, Germany) RP C18 column (250 .2 mm i.d., 5 µm) using acetonitrile:water 
(containing 0.1% formic acid) for elution in a gradient from 7:3 to 9.5:0.5 in 3 min, followed by 
isocratic elution with 0.5:9.5 between 3 and 21 min, and finally isocratic elution with acetonitrile 
from 24 to 25 min. The flow rate was 0.4 mL/min throughout. The MS/ESI traces recorded was 
positive ions from m/z 100 to1500. A MS software (Applied Biosystem ESI software, CA) was 
used to differentiate between peaks resulting from treatment effect and background noise peaks. 
Only mass/charge ratio [M/Z]+ of peaks resulting from the treatment are shown. 
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Statistical analysis   
All data was analyzed by the SAS statistical system, version 8.2.  The cell number, cell 
cycle and HPLC quantification were analyzed by the 1-way ANOVA protocol using the general 
linear model procedure followed by Fisher’s protected least square difference. For figure 2.1 and 
figure 2.3, the variable was the lignan amount at 0-40 μM. The relationship between lignan 
concentrations remaining in cell culture medium and the original lignan amounts was determined 
by a two-tailed t test. A probability ≤ 0.01 was considered significant as represented by the 
asterisk. 
Results 
Cell growth inhibition  
Human cancer cells treated with either SDG or enterolactone showed a growth inhibitory 
effect. The treatment of SW480 cells with SDG and enterolactone at 0-40 µM resulted in dose 
and time dependent decrease in cell number compared to vehicle control (Figure 2.1). The 
inhibition increased with increasing concentration of SDG or enterolactone. 
Cytotoxicity  
Cell viability was generally >80% in adherent cells, and the treated cells did not differ 
from the vehicle controls (Figure 2.2). 
S-phase cell cycle arrest at 24 and 48 hrs 
The treatment of SW480 cells with either SDG or enterolactone induced cell cycle arrest 
at S-phase in a dose and time dependent manner (Figure 2.3). DNA flow cytometry profiles 
indicated that S-phase was significantly increased with SDG and enterolactone treatment. As the 
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percentage of cells in S-phase increased, the percentage of cells at both G1 and G2/M phases 
decreased correspondingly (data not shown). 
HPLC chromatogram of SDG and enterolactone in medium 
HPLC showed that SDG and enterolactone are depleted in the cell culture medium over 
time. A HPLC chromatogram for reference standards; SDG, enterolactone and enterodiol is 
presented in Figure 2.4A. The order of lignan elution and retention time was SDG, enterodiol 
and enterolactone at 20.5, 25.4 and 28.6 mins respectively. The HPLC chromatogram of medium 
treated with either SDG and enterolactone alone are presented in Figure 2.4B and 2.4C 
respectively. 
HPLC quantification of SDG and enterolactone in medium with and without cells for 
stability analysis 
The quantification of SDG and enterolactone in medium with cells was done with 0-40 
µM SDG and enterolactone respectively for 48 hrs as shown in Figure 2.5. The data was used to 
calculate stability of the lignans in medium. Stability was investigated further with 40 µM SDG 
vs. enterolactone for 48 hrs without SW480 cell usage. 
HPLC chromatogram of SDG and enterolactone in intracellular cancer cell extracts 
HPLC chromatograms for SDG, enterodiol, enterolactone and internal standard, flavone 
is presented in Figure 2.6. The chromatogram for commercial SDG standard is shown by Figure 
2.6A. HPLC analysis of intracellular extracts of cancer cells detected enterolactone levels in 
enterolactone treated cells as shown in Figure 2.6B. However, SDG was not detected in 
intracellular extracts of cancer cells treated with SDG as shown in Figure 2.6C. 
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HPLC-MS/ESI analysis of intracellular extracts of cancer cells treated with 
enterolactone and SDG 
A HPLC-MS/ESI chromatogram showing the fragmentation pattern of commercial lignan 
standard, enterolactone is shown in Figure 2.7A. The major ion had a mass/charge ratio [M/Z]+ 
of 298.5 and can be identified as enterolactone. The intracellular extract chromatogram of cells 
treated with 40 µM enterolactone is shown in Figure 2.7B. Peak with [M/Z]+ of 298.47 confirms 
the intracellular presence of enterolactone in enterolactone treated cancer cells. Peak with [M/Z]+ 
217.98 is a contaminant plastic peak associated with the column used and [M/Z]+ 857.03 was 
determined to be a true fragmentation peak from the enterolactone treatment.  HPLC-MS/ESI 
chromatogram of commercial lignan standard SDG is presented in Figure 2.8A. The major ion 
peak has a [M/Z]+ ratio of 704.09 and can be suggested as SDG combined with a molecule of 
water [M+H2O]+. The commercial standard SDG has molecular mass of 687 and is shown in 
[M/Z]+ of 687.02. The intracellular extract chromatogram of cells treated with 40 µM SDG is 
also shown in Figure 2.7B. Peaks with [M/Z]+ of 341.31, 398.0, 472.12 and 917.09 were 
identified as authentic new peaks that were absent in the HPLC-MS/ESI chromatogram of 
intracellular extract of vehicle control (data not shown). 
Discussion 
Although it is known that SDG undergoes bacterial fermentation to generate lignan 
metabolites that have cancer preventive activity, little information is available about the potential 
cancer preventive property of SDG. In this present study, we show that SDG inhibits colon 
cancer cell growth by inducing S-phase cell cycle arrest in a dose and time dependent manner, a 
characteristic previously associated mostly through its metabolite, enterolactone. In addition, not 
only does SDG inhibit colon cancer growth but it is also more stable (95%) than enterolactone 
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(57%) in cell culture medium. Intracellular extraction of lignans to detect for their bioavailability 
through HPLC-MS/ESI confirmed the presence of enterolactone in enterolactone treated cells 
and potential metabolite peaks in SDG treated cells. 
We used human cancer cell line SW480 for our studies because previous studies had 
indicated that this cell line is sensitive to enterolactone and enterodiol (9) 
In this study, we assessed the effect of different doses of commercially available SDG on 
human colon cancer cell growth. It was found that cancer cell growth was significantly inhibited 
by SDG treatment.  Increasing SDG dosage (0-40 µM) did not kill the cancer cells as cell 
viability was not affected but instead resulted in S-phase cell cycle arrest as measured by DNA 
flow cytometry analysis. 
Stability analysis of lignans through quantification with HPLC showed that SDG is 
almost twice stable (95 %) in medium compared to enterolactone (57%).   Structure stability of 
lignans may be determined by the nature of chemical forces involved in the bonding of the 
inherent structure and by the attached chemical groups. SDG is bulky with two glucose bonds 
attached to its structure and therefore has higher entropy than enterolactone making it more 
kinetically stable. In addition, the bulky glucose moieties in the SDG structure may prevent 
attack from possible electrophiles in cell culture medium. In addition, the presence of methoxy 
groups attached to outer carbon benzene rings in the SDG structure allow for increased electron 
delocalization and hence more stability in the inherent SDG structure (19).  This may also 
explain why SDG remains stable in bread products during baking (20). On the other hand, the 
reactive lactone group on enterolactone tends to make it unstable as has been shown seen in 
antibacterial studies using lactone functional groups (21, 22). In addition, the accessibility of 
enterolactone functional groups to possible attacks by potential electrophiles is high. Although, 
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ChemDraw ultra software (23) predicts a negative overall enthalpy on the enterolactone 
structure, the lactone functional group and the openness of the enterolactone structure tend to 
overshadow this positive effect towards increased enterolactone instability.  However, we did not 
detect any new breakdown peaks in the HPLC stability chromatogram of enterolactone compared 
to SDG (Figure 2.4). 
Intracellular level studies detected enterolactone in intracellular extracts of cancer cells 
treated with enterolactone but four (4) unknown peaks were detected in SDG treated cells. 
HPLC-MS/ESI confirmed enterolactone as a molecular ion with a mass/charge ratio ([M/Z]+ of 
298. A new novel unknown peak with the [M/Z]+ 857 was also identified in enterolactone treated 
cells. Further fragmentation ion analysis, indicated that [M/Z]+ 857 was a true peak probably for 
a new metabolite compound.  We suggest here that [M/Z]+ 857 is probably a high molecular 
weight compound obtained through a 5’ 5’ coupling reaction or through conjugation with other 
compounds. On the other hand, HPLC-MS/ESI chromatogram of cancer extracts treated with 
SDG showed [M/Z]+ 341.31, [M/Z]+ 398, [M/Z]+ 472.12. The [M/Z]+ 341.31, [M/Z]+ 398, and 
[M/Z]+ 472.12 are suggested to be products of SDG breakdown within the cell since their [M/Z]+ 
are less than the SDG [M/Z]+ of 687.02. A high molecular weight peak, [M/Z]+ 917.09 was also 
detected which probably represents a peak formed through a SDG 5’5’ coupling reaction 
occurring intracellular within cancer cells. 
In conclusion, SDG had significant anticancer effects in inhibition of human colon cancer 
cell growth as seen with S-phase cell cycle arrest in a dose and time dependent manner. HPLC 
stability analysis of the cell culture medium treated with SDG or enterolactone indicated that 
SDG was more stable than enterolactone. Bioavailability studies revealed that enterolactone is 
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bioavailable in enterolactone treated cells while the unknown metabolite peaks in SDG treated 
cells could be associated with the cancer preventative impact in these treatments 
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 Figure 2:1 Comparison of SDG vs. enterolactone in SW480 cells for cancer growth 
inhibition analysis 
Cells were cultured with either 0-40 µM SDG or enterolactone for 24 and 48 hrs. Cell count was 
performed with a hemacytometer.  Percentage of cells at each treatment was compared to vehicle 
control and is represented as ± SD from 7-11 independent experiments.  Means within a 
treatment without a common letter differ, p ≤ 0.05 
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 Figure 2:2 Cell vialability analysis 
Cell vialability analysis to detect for total number of live cells in cancer growth inhibition 
analysis of SW480 cells treated with 0-40 μM concentrations of SDG vs. enterolactone measured 
by trypan blue staining. No significant difference was observed between treatments. 
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 Figure 2:3 Comparison of SDG vs. enterolactone in SW480 cells in S-phase cell cycle 
analysis 
Cells were cultured with either 0-40 µM SDG or enterolactone for 24 and 48 hrs and cell cycle 
change was measured through use of DNA flow cytometry.   Percentage of cells in S-phase was 
compared to vehicle control and is represented as ± SD from 5-7 independent experiments for 
SDG treated cells and 3-4 independent experiments for enterolactone treated cells.  Means within 
a treatment without a common letter differ, P ≤ 0.05. 
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 Figure 2:4 HPLC chromatogram of lignans treated in cell culture medium 
Representative HPLC chromatograms of commercial lignan standards: SDG, enterodiol and 
enterolactone (A). Cells were treated with 40 µM of either SDG or enterolactone, centrifuged to 
obtain a supernatant that was run on HPLC to detect for remaining enterolactone (B) vs. for 
remaining SDG (C). 
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Figure 2:5 Stability analysis of SDG vs. enterolactone in medium with and without SW480 
cells 
SDG and enterolactone were treated 0-40 μM in SW480 cells for 48 hrs and the concentration of 
lignans remaining quantified by HPLC. Stability analysis was also done without SW480 cells at 
40 μM SDG or enterolactone for 48 hrs. Stability of SDG vs. enterolactone is represented as ± 
SD from 3-4 independent experiments.  Means within a treatment represented by a asterisk 
differ, P ≤ 0.01 
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 Figure 2:6 HPLC chromatogram of lignans from intracellular extractions from cancer cells 
Representative HPLC chromatograms of commercial lignan standards: SDG, enterodiol, 
enterolactone and internal standard, flavone (A). Cells were treated with 40 µM of either SDG or 
enterolactone, centrifuged to obtain a pellet containing cancer cells. Cancer cells were then 
extracted for intracellular lignans as described in the material and methods. HPLC 
chromatograms for intracellular detection of enterolactone (B) and SDG (C) are presented.  
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Figure 2:7 HPLC-MS/ESI chromatograms of lignans after intracellular extractions with 
enterolactone 
Representative HPLC-ESI/MS chromatograms of commercial lignan standard, enterolactone is 
shown (A). The major peak is [M/Z]+ 298.5 representing molecular mass of enterolactone. A 
HPLC-ESI/MS chromatogram of intracellular extract from cancer cells treated with 
enterolactone is shown (B). The major peaks [M/Z]+ 217.98 is a plastic contaminant, [M/Z]+ 
298.47 confirms intracellular bioavailability of enterolactone, and [M/Z]+ 857.03 is a unknown 
peak from enterolactone treatment.  
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 Figure 2:8 HPLC MS/ESI chromatograms of intracellular extracts of cancer cells treated 
with SDG 
Representative HPLC-MS/ESI chromatograms of commercial lignan standard SDG with [M/Z]+ 
687.02 and SDG [M+ H20]+ 704.09 (A). Unknown peaks (peak 1 to peak 4) with [M/Z]+ of 
341.31, 398.0,  472.12 and 917.09 were detected after intracellular extraction of cancer cells 
treated with SDG. 
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Summary 
Lignans are phytochemicals that have been shown to have cancer preventive activities in 
animal models. Our previous studies demonstrated that the contents of lignans in various wheat 
cultivars were significantly associated with anti-tumor activities. Phytochemical lignans are 
biosynthesized via the phenylpropanoid pathway, in which pinoresinol lariciresinol reductase 
(PLR) catalyzes the last steps specifically for lignan production. To enhance lignan biosynthesis, 
we transformed wheat cultivars (‘Bobwhite’, ‘Madison’, and ‘Fielder’ respectively) with the 
Forsythia intermedia PLR gene under the regulatory control of the maize ubiquitin promoter. Of 
217 putative transgenic wheat lines, we successfully obtained 7 transformants with the inserted 
ubiquitin PLR gene as screened by PCR. Southern blot analysis further demonstrated that 
different copies of the PLR gene were carried in these wheat genomes. Furthermore, real-time 
PCR indicated 109-117% over-expression of PLR gene over the control in 3 positive 
transformants at the T0 generation. In addition, the levels of secoisolariciresinol diglucoside, a 
prominent lignan whose biosynthesis is catalyzed by PLR as determined by HPLC, were found 
to be significantly elevated in one of the three positive transgenic plants. To the best of our 
knowledge, this is the first study that elevated lignan levels in transgenic wheat has been 
successfully achieved through genetic engineering of the over expressed lignan biosynthesis 
enzyme. 
Introduction 
Lignans are phenylpropane dimers linked by β-β bonds with a 1,4 – diarylbutane 
structure [1, 2]. They occur naturally in a number of plant families, including the gramineae and 
oleaceae which contain the monocots and eudicots respectively [3, 4].  In monocots such as 
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wheat, lignans are mostly located in the aleurone layer of seeds [5] and in eudicots such as 
forsthysia, lignans occur in the fruits and stems [6]. Also in eudicots, lignans are formed through 
dimerization of alcohols in the phenylpropanoid pathway through skeletal rearrangements and 
oxygen incorporation [3] while in monocots, literature review on the phenylpropanoid pathway 
is scarce.  
The biological importance of lignans has also recently been reviewed [7, 9]. 
Epidemiological studies show an inverse association between dietary intake of lignans and the 
risk of cardiovascular disease [10, 11]. Lignans also have potential protective roles in breast [12], 
prostate [13], and colon cancers [14, 15]. A recent study done in rats showed that exposure of 
10% flax seed or secoisolariciresinol diglucoside (SDG) during suckling suppressed DMBA-
induced mammary tumorigenesis [16]. Studies in animals are supported by in vitro cell culture 
results that show that lignan metabolites reduce growth and metastasis of breast cancer cells [17]. 
Furthermore, in colon cancer cells, lignan metabolites have been shown to reduce cell growth by 
our previous publication [18]. In both studies, cancer growth inhibition could be correlated to the 
amount of lignans used. More specifically, the correlation between cancer cell growth inhibition 
and anti-tumor activity was found with the lignan, SDG as in our previous study (r = 0.73, p < 
0.02) [18]. Higher SDG amounts may therefore mean higher anti-tumor activity. As a result, 
increase of the SDG levels in wheat plants may provide more lignans for cancer preventive 
effects. 
Cancer preventive SDG in wheat may therefore be increased through genetic 
manipulation methods as shown by others [19, 20]. Genetic manipulation of the phenylpropanoid 
pathway through targeting of enzymes that catalyze entry of first and last lignans into this 
pathway may present a novel approach for enhanced lignan biosynthesis. One of the key control 
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enzymes, pinoresinol lariciresinol reductases (PLR) which catalyzes the last steps of the lignan 
biosynthesis pathway can be genetically engineered to increase lignans [21]. To do this, we may 
use any of the PLR genes already isolated from woody plants (3, 22, 23], and also most recently 
from flax seeds [24]. In wheat, the full-length PLR gene is yet to be isolated. 
The purpose of this study was therefore to enhance SDG biosynthesis in transgenic wheat 
plants by genetic transformation of wheat with the F. intermedia PLR cDNA. To the best of our 
knowledge, this is the first study to apply genetic engineering of wheat for lignan biosynthesis 
enhancement. 
Materials and methods 
Plasmid construction of Ubi PLR 
We obtained the F. intermedia PLR cDNA as a kind gift from Dr. Lewis Norman 
 of Washingston State University. The PLR cDNA was initially cloned into a pGem Teasy vector 
(Promega, Madison, WI) and then subsequently PCR modified by primers BgL 1 F and BgL 1 R 
for insertion of BgL 1 sites at the 3’ and 5’ end (Table 3.1). The PLR gene was then placed under 
the control of the maize ubiquitin promoter, pAHC 17 [25]. The new generated plasmid 
designated as ‘Ubi PLR’ was used for co-transformation purposes with the bar gene, pAHC 20. 
Co-transformation and tissue culture of wheat with Ubi-PLR 
Vector plasmids, Ubi PLR and the selectable marker gene, pAHC 20 [25] (plasmid for 
the bar resistance gene) were co-bombarded into embryogenic calli of wheat (cultivars 
‘Bobwhite’, ‘Madison’ and ‘Fielder’). The method of co-transformation and selection of 
transgenic events have been detailed by Anand et al 2003 [26]. Briefly, premature seeds were 
surface sterilized with 20% sodium hypochlorite and 0.02% TWEEN-20 and embryos aseptically 
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excised on CM4 medium to initiate somatic embryo formation. Somatic embryos that 
proliferated on CM4+ osmoticum (0.2 M mannitol, 0.2 M sorbitol) were co-bombarded with the 
pAHC 20 and Ubi PLR plasmid by use of the particle flow gun. For co-transformation, plasmid 
DNA at a ratio of pAHC 20 to Ubi PLR of 1:1 was precipitated onto tungsten particles and 
applied on a swinney filter holder on the particle inflow gun. Helium gas with a 60 pound per 
square inch microburst was then propelled towards the target embryo. Selection and regeneration 
of transgenic plants were then done as described before [27] with slight modifications and here is 
a brief summary. Sixteen hours (16) after co-bombardment, selection for transformed tissue was 
on CM4 medium containing 5 mg l-1 glufosinate. Sub-culturing was done after 2 weeks to 
medium strength of 10 mg l-1 glufosinate. After 10-15 weeks, growing clumps transferred to 
shoot production medium, MSP containing MS [28] with glufosinate selection until green shoots 
were observed. The cultures were then transferred to elongation and rooting medium (MSE) 
containing 5 mg l-1 glufosinate and cultured 2-3 weeks. Healthy looking plantlets obtained were 
transferred to soil and grown in environmentally green house. 
Leaf painting assay for confirmation of the selectable marker, bar 
To examine the expression of the selectable bar resistance gene in the transgenic plants, 
leaf painting was done as previously described [26] and here is a brief summary. Freshly 
prepared solution of herbicide, liberty (0.2% v/v) was applied on the second/third youngest leaf 
using a cotton plug and marked off with a marker pen. Visual observations were recorded 7-10 
days after painting. Positive lines with resistant green leaves were used for PCR analysis 
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Polymerase chain reactions (PCR) for the bar, PLR and Ubi-PLR gene 
For all the three primer sets, PCR analysis was done with genomic DNA extracted from 
leaves of transgenic wheat plants using the phenol chloroform extraction method [29, 30]. In 
brief, 100-500 ng of genomic DNA from transgenic plants was screened by primer sets; Bar AB 
F and Bar AB R, PLR F and PLR R, and Ubi PLR F and Ubi PLR R (Table 3.1) in a PTC-220 
thermal Cycler (Hybaid Limited, Hastings, UK). Samples were denatured, annealed and 
extended at 940C, 58-60 0C, and 720C for 1 minute, 30 sec and 45 sec, respectively for 35 cycles. 
PCR products were visualized through 1.8% agarose gel electrophoresis. Only transformants that 
tested positive with the three primer sets positive were used for confirmation of transgenic 
success. 
Southern blot analysis of positive transgenic wheat lines for detection of integration of 
the Ubi-PLR gene combination 
About 25 µg of isolated genomic DNA isolated was fully digested with a single enzyme 
cutter, Bam HI and separated by electrophoresis in 0.8% agarose (30V) in 12-14 hrs. Genomic 
DNA was denatured and transferred onto Hybond N+ membrane using a alkaline transfer 
procedure described by Amersham (Amersham, Piscataway, NJ). The detection of introduced 
DNA was performed according to established protocol. Briefly, the nylon membrane was 
hybridized for 24 hrs with the 1.2kb 32P-dCTP labeled F .intermedia PLR gene. After 
hybridization, blotted membrane was exposed in a phosphor imager cassette and developed using 
the Scan Quant software (Molecular Dynamics Inc., Sunnyvale, CA) 
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Isolation of the partial Wheat PLR sequence 
To isolate the partial wheat PLR sequence, wheat genomic DNA was extracted as 
described above from wild wheat type (cultivar ‘Fielder’). Primer sets (PLR F and PLR R) were 
used to PCR amplify the wheat PLR fragment (same PCR conditions as above for PLR primers). 
The PCR products obtained were purified using the montage DNA PCR purification kit 
(Millipore Corporation, Bedford, MA) and inserted into the multiple cloning site of the pGem 
Teasy vector (Promega, Madison, WI) before sequencing with pGem Teasy vector primers. The 
sequences obtained from the vectors were then compared to Forsthysia PLR sequence as 
determined by national centre for biotechnology sequence comparison software (NCBI).  
Relative real time PCR quantification of Ubi-PLR expression in positive transgenic 
wheat plants 
To quantify for levels of F. intermedia PLR expression in different positive transgenic 
plants, total RNA was isolated from young leaf tissue by use of the total RNA isolation kit 
(Promega, Madison WI). Total RNA amounts were determined by use of the nanodrop 
(Nanodrop Technologies, Wilmington, DE) through measuring UV absorption at 260. The ratio 
of 230/260 was used determine mRNA purity. First strand cDNA synthesis was performed 
according manufacturer’s instructions using 1 µg of total RNA with AMV reverse transcriptase   
(Promega, Madison, WI). The samples were diluted to an equivalent volume and an equivalent 
amount used for real time PCR analysis. The primer set, PLR RT F and the PLR RT R, (Table. 
3.1) was used to amplify a 99bp fragment of the F. intermedia PLR gene using the SyBr green 
master mix protocol as suggested by the manufacturer (Bio-rad Laboratories, Hercules, CA). 
Real time PCR was performed with a iCycler thermal cycler (Bio-rad Laboratories, Hercules, 
CA). Ten to eighty pg of Ubi PLR was amplified to determine the efficiency of the F. intermedia 
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PLR RT primers. PCR products from the cDNA were then qualified with the iCycler Bio-rad 
software (Bio-rad Laboratories, Hercules, CA). The experiment was repeated three times and the 
results plotted as relative quantification in log CT units. 
SDG identification and quantification in transgenic wheat 
Sample extracts from transgenic wheat T2 seeds were quantified for SDG levels by HPLC 
analysis. Briefly, transgenic and non transgenic seeds (10-30) equivalent to 0.2-0.5 mg were 
ground and defatted using hexane and dried in the hood overnight. Defatted whole extracts were 
then homogenized under cold conditions through addition of liquid nitrogen. Subsequently, the 
supernatant after centrifugation was extracted for lignans with diethyl ether before evaporation to 
obtain a residue that was re-dissolved in 100% methanol. The dissolved residue was then 
subjected to HPLC with 5 mM flavone as an internal standard. HPLC-UV was done according to 
previous methods (34) with slight modification. Generally, extracts were subjected to HPLC 
chromatography on a C18 column (5 µm, 250 X 4.6 mm, Alltech), eluted with a 5% acetonitrile 
in pH 2.8, 0.01 mM phosphate buffer (solvent A) over 100% acetonitrile (solvent B) at a flow 
rate of 1 ml/min. A gradient run of 0-10 minutes in 100% solvent A, 10-30 minutes in 0-100% 
solvent B and finally 30-40 minutes in 100% solvent B was determined as optimum. The SDG 
peak was detected by monitoring absorbance at 280nm and identified by both retention time and 
mass spectrum comparison with a standard commercial SDG. 
Statistical analysis 
All data was analyzed by the SAS statistical software, version 8.2. The real time PCR 
determination of F. intermedia PLR expression levels and HPLC quantification of SDG were 
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analyzed by the one ANOVA protocol using the general linear model procedure followed by 
Fisher’s protected least square difference. A probability of ≤ 0.05 was considered significant. 
Results 
Transgenic wheat plants 
After embryogenic tissue culture selection and regeneration with the shoot production 
medium, 217 liberty painting positive wheat plants were obtained. PCR screen indicated twenty 
four putative transformants to be bar and PLR gene positive as represented (Figure. 3.3A and 
3.3B). Out of these, 3 from wheat cultivar (‘Fielder’) were positive for the Ubi PLR gene by the 
PCR screen (Figure. 3.3C).  
Detection, expression and integration of the selectable marker bar and Ubi PLR 
The selectable marker, bar was detected by both the leaf painting assay and PCR (Fig. 
3.3A). Leaf painting performed on T0, T1 and T2 leaves of transgenic wheat identified putative 
transformants after 7-10 days. Putative transformants showed tolerance to the herbicide liberty, 
but null segregates showed leaf yellowing in the same period.  PCR analysis for the ‘bar’ gene 
confirmed presence of the ‘bar’ resistance gene in some of the putative transformants (24/217 
transformants.  PCR analysis also detected the ‘PLR’ gene and ‘Ubi-PLR’ genes in the bar 
positive plants.  
For southern blot integration of the PLR gene in T0 leaves of transgenic wheat lines, we 
used T0 plant 4995 as the negative transgenic control because it was PCR positive for the ‘bar’ 
gene but not for the ‘Ubi-PLR’ gene as seen in figure 3.3A and 3.3C respectively. In addition to 
plant 4995, we also found out that plant 4907 and 5010 that showed presence of ‘PLR’ as the 
wild type plant (Fig. 3.3B-most extreme right lane) did not show presence of ‘Ubi-PLR’ (Figure 
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3.3C) perhaps suggesting to us that we would have detected the indigenous wheat PLR gene in 
these 2 transgenic plants. We later determined this to be true for the 24 positive transgenic plants 
tested (Figure 3.3C). Southern integration patterns of transgenic lines; 4995, 4907 and 5010 
helped confirm the presence of the indigenous wheat PLR gene since they had two integrations 
bands similar to the wild type plant (Figure 3.4). On the other hand, southern integration patterns 
of  3 positive transgenic lines showed more than 2 integrated bands of  PLR with the single 
enzyme cutter i.e. BamH1. T0 plants 4962 and 4909 had similar 3 major hybridization bands 
while T0 plant 4970 with 5 major hybridization bands. 
Real time PCR quantification of the PLR gene in transgenic plants 
Quantitative real-time PCR was used to quantify for the expression of the F. intermedia 
PLR gene (Figure 3.5). Quantification of the relative differences in transgene expression of PLR 
using real time PCR revealed that plant 4970 and 4962 had significantly higher levels (~ 6.2 
relative units)  than the transgenic control plant 4995 (~ 5.4 relative units). 
Detection and quantification of SDG in transgenic wheat T2 seeds 
We then determined the SDG amount in transgenic wheat T2 seeds through HPLC as a 
measure of the functionality of transformation process (Figure. 3.6). The HPLC SDG peak 
confirmed by mass spectrometry had a mass to charge ratio of 688 similar to that of commercial 
SDG.  T0 plant 5010 whose 2nd generation seeds are T2 5010 A2 (A2 - The A represents the 1st 
generation letter annotation used for differentiating between individual transgenic lines in the 
same transformation event while the 2 represents the 2nd generation numeral annotation used for 
individual transgenic lines) is used as the negative transgenic control plant because earlier results 
indicated that it had similar hybridization patterns to the transgenic control plant, 4995.  It was 
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therefore not surprising to find that T2 5010 A2 seeds had the lowest amount of SDG. The SDG 
amount was highest in the T2 wheat seeds of plant 4970 I5 (Figure. 3.6C), which are 2nd 
generation seeds from T0 plant 4970. The seeds of T2 4970 I5 came from T0 plant 4970 whose 
leaf extracts had the highest levels of the PLR transcript as shown earlier (Figure 3.5). T0 plants 
4909, 4970, 4970  whose 2nd seed generations are T2 seeds 4909 E5, 4970 B1 and 4970 A3, 
respectively were also relatively high in SDG amount but not significantly different from 
transgenic control plant 5010. The overall percentage increase in SDG amount varied was about 
3-fold compared to transgenic control or the wild type non-transgenic control.  
Discussion 
Of the 217 transgenic wheat plants obtained after co-bombardment with the  
constructed Ubi PLR plasmid, 3 shown here were positive for ‘bar’, ‘PLR’ genes and Ubi-PLR 
gene combination.  Putative transgenic plants and control lines showed similar morphological 
characteristics. The southern blot indicated integration of one (1) or more additional ‘copies’ of 
PLR in plants that were genetically positive. Relative real time PCR quantification showed an 
increase in relative expression of PLR from 5.4 to 6.2 units, a value equivalent to 109-117% PLR 
over-expression over the control.  Quantification of the PLR biosynthesis product, SDG showed 
a 3 -fold increase in lignan amount compared to the non transgenic control. 
Putative transformants that survived the selection process, were screened for the presence 
of the ‘bar’ gene by leaf painting and then PCR analysis. Plants whose leaves survived painting 
with the herbicide liberty and showed positive PCR bands for the ‘bar’ gene were considered as 
successful transgenic lines for next analysis. Escapes were considered as plants that survived the 
selection process but were in fact not transformed. Such plants were liberty painting positive but 
‘bar’ PCR screen negative. Confirmation by PCR analysis of the ‘PLR’ gene identified 24 
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positive transgenic plants out of 217 transformants for both the ‘bar’ and ‘PLR’ genes. PCR 
analysis of the ‘PLR’ gene turned out to indicate that all plants were positive for the gene 
regardless of its background including the wild type cultivar, fielder. PCR analysis of the Ubi 
PLR gene combination on the other hand detected plants that had  Ubi PLR gene combination.  
In some positive transgenic plants, we detected the ‘bar’ and ‘PLR’ gene but not Ubi-PLR. 
Those plants such as 4995, 4907 and 5010 suggested to us that the detected ‘PLR’ gene could 
have come from another source i.e. the indigenous wheat ‘PLR’ gene. This was later proved 
when we isolated and sequenced the partial sequence of the wheat PLR gene and found that it to 
share 98% sequence similarity to the F. intermedia PLR gene sequence (Figure 3.5). 
To determine the integration pattern of Ubi PLR gene combination in the wheat genome, 
We performed a southern blot where we used a single site enzyme cutter, BamH1 which cuts the 
PLR gene at the 47th position. We also used the same enzyme for wheat genomic DNA digestion. 
When the southern blot was probed with the 1.2 kb gene fragment of the F. intermedia PLR, 
different numbers of integrated hybridization bands were observed. Surprising, all transgenic 
wheat lines including the transgenic control plant 4995 detected the presence of an integrated 
hybridization band at the ~1.2 kb position. This band was also present in the wild type wheat 
fielder cultivar. This further confirmed our initial PCR experiments above which were suggestive 
of the indigenously expressed wheat ‘PLR’ gene in wild type control.  
In addition to that, differences in number and patterns of other hybridization bands [5 
different bands in 4970, 2 in 4909& 4962 and 1 in 4995] were observed and these suggested that 
these plants may have arose from different transformation events. Different transformation 
events will produce plants with different copy numbers of the PLR gene mainly because of the 
unpredictability of the particle inflow gun [31].  BamHI cuts the Ubi PLR gene combination at 
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the 47th  base position from the 5’ end of PLR gene in the gene combination (Figure 3.4) and 
therefore may create two integration bands, one very strong (from the longer length fragment, < 
1.2 kb) and another, weak one (from the fragment length fragment, observed close to the < 0.047 
kb). For negative plants, the second bar will be weak as seen with 4995, 4907 and 5010 as also 
seen with the wild type band because of their single PLR gene copy while for positive transgenic 
plants, the second band will be stronger if there is an additional longer PLR gene fragment as 
observed with transgenic plants 4962 and 4909. Plant 4970, on the other hand showed five major 
hybridization bands probably indicating integration of more PLR genes.  
Also, other authors have suggested that co-transformation experiments with the ‘bar’ 
gene could result into multiple copies of the unselected gene [32]. However, it is not clear 
whether high copy number may translate into higher transcript level of the PLR gene. 
To quantify for relative PLR expression, we used a real time PCR technique to estimate 
for expression levels of ‘PLR’ transcripts in transgenic wheat leaves. Relative real time PCR 
expression indicated a variation in expression from 5.4 to 6.2 units (Figure 3.6). This variation 
was equivalent to a 109-117% over-expression of PLR over the transgenic control. The variation 
in expression would have resulted from the difference in expression of PLR between different 
transformation events.  The variation could have also resulted from difference in expression of 
‘PLR’.  The variation in difference in expression of ‘PLR’ can be evidenced through southern 
blot data which indicates that different transgenic wheat lines had different number of ‘PLR’ 
hybridization bands probably due to difference in copy numbers of PLR being expressed. Lower 
‘PLR’ copy numbers could mean lower PLR relative expression.  However, further analysis 
indicated that transgenic plant 4970 which had 5 hybridization bands (indicative of 5 ‘PLR’ 
copies) had the similar expression level as plant 4909 with only 2 hybridization bands hence 
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suggesting difference in number of integration bands was not sufficient to explain for variation in 
expression levels. Perhaps gene silencing, biological variation or segregation of the ‘PLR’ gene 
would have occupied in the transgenic plants with high copy number of PLR such as plant 4970. 
The later phenomenon usually occurs in genes whose expression is under the control of the 
ubiquitin promoter [33].  
However, stability analysis of the ‘PLR’ gene in T2 seeds did not detect the PLR PCR 
amplicon perhaps suggesting that the experiments above need to be verified. In addition, another 
possible reason for failure to detect for PLR in T2 seeds could be, because the homozygosity of 
the PLR gene was not established. Seeds used for SDG quantification could have come were 
from heterozygous lines and therefore when PCR analysis is performed on these (as per 
mendelian genetics ratio of inheritance of genes assuming independent assortment; 3:1, dominant 
to recessive inheritance), no products will be detected if the seeds were obtained from the 
recessive line. In addition, gene silencing at later generations rather than the T0 generation is 
usual in transgenic wheat plants [34, 35].  Also, the PLR integration bands observed in the T0 
plants could have resulted from transient expression.  
Finally, we determined the levels of SDG, and found that transgenic wheat plants 
showing the highest level of PLR expression had the highest amount of SDG. Comparison with 
the wild type control plant suggested that the levels of SDG were ~ 3 fold significantly higher in 
positive transgenic wheat line, 4970I5 that over-expressed PLR. The elevated levels of SDG 
therefore could have occurred from increased first generation synthesis of SDG. Elevated SDG 
levels also mean increased anti-tumor activity from ~ 30% to 60% as seen in previous study from 
the Wang Lab [26 chapter 2). 
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This is the first report that shows the genetic transformation of wheat for the purposes of 
increased accumulation of SDG.  Stable expression of the F. intermedia PLR gene probably 
through use of a separate promoter or different transformation method is suggested as an 
alternative for SDG manipulation in wheat plants.  Targeting other enzymes such as 
phenylalanine ammonia lyase (PAL) by pathway transformation may provide an opportunity for 
manipulation of more than one gene involved in lignan biosynthesis for enhanced lignan levels. 
Isolation of the full-length wheat PLR gene is a scientific pursuit for future genetic 
transformation purposes. 
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 Table 3.1 PCR primers used for plasmid construction and analysis of transformants 
Primer set Primer sequence Position 
in DNA 
Amp 
licon  
size 
(bp) 
PLR Bg1 L  F:  
                    R:    
5’ AGG AGG ATC TGA ATT  CGC CAC GAG 3’ 
5’ AGG AAG ATC AGC AAA ATT CAA CAC TAT TAT T 
3’ 
Insert 
Insert 
N/A 
           PLR  F: 
                    R:    
5’ TCG TAG ACG TAG TAA TCA GCG CCA 3’ 
5’ TCG AGC TCT TTC ACG GAG GCT AAA 3’ 
260 
799 
539 
Ubi PLR      F:  
                    R:    
5’ GAT GCT CAC CCT GTT GTT  TGG TGG TGT 3’ 
5’ AGG AAG ATC AGC AAA ATT CAA CAC TAT TAT T 
3’ 
1974 
2557 
583 
Bar AB        F:  
                    R:    
5’ CCT GCC TTC ATA CGC TAT  TTA TTT 3’ 
5’ CTT CAG CAG GTG GGT GTA GAG CGT G 3’ 
1958 
14 
600 
PLR RT       F:  
                    R:    
5’ ATC CAA GAA CCC TCA ACA AGC TGG TGT 3’ 
5’ TCC CAT GTC TGA ACA ATT CTC 3’ 
110 
209 
99 
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 Figure 3:1 The phenylpropanoid pathway showing the final enzymatic stages of lignan 
formation catalyzed by pinoresinol lariciresinol reductase 
The phenylpropanoid pathway showing the enzymatic stages of lignan formation catalyzed by 
other enzymes and pinoresinol lariciresinol reductase. Pinoresinol lariciresinol reductase 
catalyses the last critical final stages of the pathway for SDG biosynthesis. 
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Figure 3:2 A schematic representative of the ‘bar’ and Ubi PLR plasmids showing 
locations of expected amplicon sizes 
‘Bar’ plasmid has the ubiquitin promoter and the nos terminator.  ‘Ubi PLR’ contains the 
ubiquitin promoter, the PLR gene insert and the nos terminator segments. 
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Figure 3:3 PCR screening for transgenic wheat plants run on 1.8% agarose gel 
electrophoresis 
The first lane on the far left on each gel strip, A to C is M for the molecular weight marker used. 
The next seven lanes are representative of different transgenic plants tested. A is the 
representative strip of a 539bp forsthysia PLR amplicon. B is a 600bp bar gene amplicon. Also 
shown in B, the PLR amplicon obtained from PCR analysis of wild type wheat cultivar. C is a 
583bp Ubi PLR amplicon.  
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Figure 3:4 Southern blot analysis showing integration patterns of different positive 
transgenic plants. 
BamH1 was used to cut genomic DNA and the probe used was 1.2 kb forsthysia PLR probe. 
Transgenic T0 plant 4970 has 5 hybridization bands, while 4962 and 4909 have three major 
hybridization bands. Transgenic negative plant 4995, 5010 and 4907 showed two major 
hybridization bands. The PLR bands resulting from running the wild type control DNA are 
shown on the right end blot, together with the molecular weight markers, M. 
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 Figure 3:5 The partial sequence of the isolated wheat PLR gene (~ 50% length of the 
Forsthysia 1.2 kb PLR gene). 
Comparison of the partial sequence of the wheat PLR gene through the NCBI database indicated 
98% sequence similarity to the Forsthysia PLR gene. 
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Figure 3:6 The quantification of PLR transcript levels in transgenic wheat lines, T0 
generation plants, 4995, 4962, 4970 and 4909 
Relative PLR mRNA expression was obtained in log CT units (y-axis) in 3-4 independent 
samples. Relative PLR expression is represented as ± SD from 3-4 independent experiments.  
Means within a treatment without a common letter differ, P ≤ 0.05. 
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Figure 3:7 HPLC analysis and quantification of SDG in transgenic wheat 
Representative HPLC chromatograph of commercial SDG (A) and of SDG extract from 
transgenic wheat seeds (B). Representative HPLC MS/ESI of SDG peak in B identified as peak 
with M/Z+ [688] (C). The quantification of SDG in transgenic wheat plants were compared to 
both the non transgenic control (fielder) and the negative transgenic control (plant 5010A2) (D). 
 76
SDG amount is represented as ± SD from 3-5 independent experiments.  Means within a 
treatment without a common letter differ, P ≤ 0.05. 
 
Appendix A - Detailed methods for Chapter 2 
Cell culture and treatment 
The human colon cancer cells, SW480, were purchased from the American Type Culture 
Collection (Rockville, MD) and cultured in Dulbecco’s Modified Eagle Medium supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis MO). 
The cells were cultured in either 6-well plates or 200 ml volumetric flasks at 37 0C in 5% CO2  
until 60-80% confluence. At this confluence, cells were treated with SDG and enterolactone, at 
0-40 µM for 24 and 48 hrs, at which time the cells had reached <100 % confluence. To perform 
treatment, SDG (99% purity) and enterolactone was purchased from ChromaDex (Irvine, CA) 
and/ or Sigma-Aldrich (St Louis, Mo) respectively, dissolved in DMSO to make a final 
concentration of 20 mM which served as the stock solution for making other concentrations. To 
make 1000 ml with a final concentration of 40 µM, 2 ul of 20 mM was dissolved in 10 ml of 
medium, vigoursly shaken on table top mixer and added to 990 ml of medium. The same method 
was also used for making other concentrations of SDG and enterolactone. After treatment cells 
were detached and counted by hemacytometer as our previously reported. To detach cells, the 
medium used was first poured, then a aliquot of trypsin/EDTA solution, was carefully added to 
6-well plate containing the cells, put back into the incubator, and allowed to incubate for 5-10 
minutes. Detached cells obtained were transferred into a centrifuge tube for counting. To count, 
cells were stained in a 1:1 ratio with trypan blue and an aliquot transferred to a glass slide and 
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put under a focal microscope. The heamocytometer placed next to the microscope was then 
pressed with each visual count of cells. 
 
Cytotoxicity Assay 
The cell viability was measured in adherent cells by trypan blue staining. The viable cell 
numbers in treated cells were compared with that in vehicle controls. To measure cell viability, 
only live cells were counted as outlined in the cell culture and treatment method above. Live  
were not stained with the trypan blue dye and therefore were clear under the microscope. 
Cell cycle analysis 
To perform cell cycle analysis, cells were obtained after treatment as outlined in the cell 
culture methods and treatment above, except that a cell scrapper was used to detach cells instead 
of  the trypsin/EDTA solution. Cells obtained were fixed in an aliquot of ethanol, centrifuged at 
1500 X g for 10 minutes and the supernatant poured out.  The pellet was resuspended in 
phosphate buffer saline solution, pH 7.4, containing 20 g/L propidium iodide and 5000 U/L of 
RNase (Promega, Madison WI) and incubated at 37 0C for 30 min on a water bath.  DNA flow 
cytometric analysis (FACSCaliber, Becton Dickinson, Newyork, NJ) was performed by blanking 
the flow cytometer with a phosphate saline solution before measurement of either SDG or 
enterolactone treated cancer cells. The excitation wavelength was at 488 nm and emission at 630 
nm. The obtained information was further analyzed with the cytometer software to calculate 
percentages of cells in different cell cycle phases. 
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HPLC quantification of SDG and enterolactone in cell culture medium 
HPLC-UV quantification of SDG and enterolactone was done according to previous 
methods with slight modification. Generally, cell culture medium containing remaining lignans 
was separated from cancer cells that had been treated with either 0-40 µM SDG or enterolactone 
by centrifugation at 1000 X g for 10 minutes.  An aliquot of the supernatant was transferred to 
HPLC vials and run on a HPLC column whose baseline had been stabilized for at least 30 
minutes with 100% solvent A.  SDG and enterolactone were separated by HPLC 
chromatography on a C18 column (5 µm, 250 X 4.6 mm, Alltech), eluted with a 5% acetonitrile 
in pH 2.8, 0.01 mM phosphate buffer (solvent A) over 100% acetonitrile (solvent B) at a flow 
rate of 1 mL/ml. A gradient run of 0-10 minutes, 100% solvent A, 10-30 minutes, 0-100% 
solvent B and finally 30-40 minutes, 100% solvent B was determined as optimum.  Peaks were 
detected by monitoring absorbance at 283nm. The enterolactone and SDG peak was identified 
according to both retention time and spectrum by comparison with a standard commercial SDG 
and enterolactone. A linear HPLC calibration curve for both lignans were obtained for the 
concentrations 0-100 µM.  
HPLC quantification of SDG and enterolactone in cancer cell extracts 
SW480 cells treated with 40 µM SDG or enterolactone for 48 hrs were harvested by 
detaching with trypsin-EDTA as previously described and centrifuged at 1000 X g for 10 
minutes. The supernatant was discarded, and the pellet was washed with 0.01 M phosphate 
buffer saline solution, pH 7.4. The collected cells were then resuspended in washing buffer, and 
sonicated under an ice bucket for 3 minutes. The extract was then subjected to lignan extraction 
with three consecutive 1:1 diethyl ether extractions. The upper organic phase containing the 
 79
lignans was obtained and evaporated to dryness by passing a stream of nitrogen gas through it. 
The resulting residue was dissolved in 100% methanol and subjected to HPLC using the method 
described above. 
Mass spectrometry analysis of intracellular extracts of cancer cells treated 
with SDG and enterolactone 
SW480 cells treated with 40 µM SDG or enterolactone for 48 hrs were harvested by 
detaching with trypsin-EDTA as previously described and centrifuged at 1000 X g for 10 
minutes. The supernatant was discarded and the pellet washed and resuspended in 0.01 M 
phosphate buffer saline solution, pH 7.4.  The resulting solution was homogenized under for 3 
minutes at high power under ice bucket. Nitrogen gas was then passed through the homogenate 
to avoid reduction conditions. The homogenate was then subjected to three 1:1 diethyl ether 
extractions. The upper organic phase containing the lignans was evaporated to dryness in a water 
bath set at 35 0C under high pressure conditions. The residue remaining at the bottom of the flask 
was re-dissolved in 100% methanol and ultra-centrifuged at 40,000 X g for 30 minutes. HPLC-
MS/ESI analysis was performed with a Finnigan LCQ Deca XP mass spectrometer (Thermo 
Finnigan, Dreieich, Germany) coupled to an Agilent (Agilent, Waldbronn, Germany) 1100 series 
HPLC system. The base line was stabilized with 100% solvent A for 3 minutes. Separations were 
achieved with a synergi (Berlin, Germany) RP C18 column (250 .2 mm i.d., 5 µm) using 
acetonitrile:water (containing 0.1% formic acid) for elution in a gradient from 7:3 to 9.5:0.5 in 3 
min, followed by isocratic elution with 0.5:9.5 between 3 and 21 min, and finally isocratic 
elution with acetonitrile from 24 to 25 min. The flow rate was 0.4 mL/min throughout. The 
MS/ESI traces recorded was positive ions from m/z 100 to1500. A MS software (Applied 
Biosystem ESI software, CA) was used to differentiate between peaks resulting from treatment 
 80
effect and background noise peaks. Only mass/charge ratio [M/Z]+ of peaks resulting from the 
treatment are shown. 
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Appendix B - Detailed methods for Chapter 3 
Plasmid construction of Ubi PLR 
A cDNA clone for PLR-Fi1 GenBank accession number U81158 encoding 
(+)pinoresinol-(+)lariciresinol reductase from Forthysia intermedia was obtained as a gift from 
Dr Lewis Norman of Washingston State University. 
Primers sets (PRL BgL 1 F and PRL-BgL 1R) (Table 1) were designed according to the 
Primer 3 software to insert BgL 1 sites at the 3’ and 5’ end of the PLR gene. Polymerase chain 
reaction (PCR) was performed using a high fecundity Taq polymerase (Bioline, Randolph MA) 
to reduce wrong sequence insertions during PCR amplication. The obtained 1.2 kb fragment was 
purified using a montage DNA gel extraction kit (Millipore Corporation, Bedford, MA) and 
inserted into a pGEM® T Easy Vector (Promega, Madison, WI). The sequence of the purified 
PLR gene product was determined using pGEM®  T Easy primer sets at the gene sequencing 
facility, plant pathology department Kansas State University. The PLR gene was then digested 
from the plasmid by use of restriction enzyme BgL 1. A plasmid (pAHC 17) that contains the 
ubiquitin gene and the nopathaline Synthetase terminator (nos) was selected and digested at the 
multiple cloning sites with BamH1 (compatible ends with BgL 1).  The purified PLR gene was 
then ligated together with the cut pAHC 17 plasmid. To ligate, 15 µl of pAHC 17 (100 ng/µl), 25 
µl of PLR cut plasmid (79 ng/µl), 8 µl of rapid T4 DNA ligase buffer (Promega, Madison WI), 
and 2 µl of T4 DNA ligase (Promega, Madison WI) was set to incubate at 4 0C overnight. The 
reaction mix was transformed into JM109 component cells (Promega, Madison WI) and selected 
with ampicillin resistance. Positive clones obtained, were grown in Luria broth (LB) medium and 
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plasmid DNA isolated using the QIAprep Miniprep Kit (Qiagen, Hilden, Germany). Restriction 
digestion with Pst I, Ecor I and Bam HI were used to confirm correct directional insertions.  
Selected clones were then, sent for sequencing with both primer sets ‘PLR F and PLR R’ 
and primer sets ‘Ubi PLR F and Ubi PLR R’ which targets the internal sequence of the ubiquitin 
PLR construct. The resulting vector plasmid with both the ubiquitin promoter and the PLR gene 
was designated as Ubi PLR. 
Co-transformation and tissue culture of wheat with Ubi PLR 
Vector plasmids, Ubi PLR and the selectable marker gene, pAHC 20 [25] (plasmid for 
the bar resistance gene) were co-bombarded into embryogenic calli of wheat (cultivars 
‘Bobwhite’, ‘Madison’ and ‘Fielder’). The method of co-transformation and selection of 
transgenic events was based on earlier methods used in the laboratory. Premature seeds were 
surface sterilized with 20% sodium hypochlorite and 0.02% TWEEN-20 and embryos aseptically 
excised on CM4+ osmoticum (0.2 M mannitol, 0.2 M sorbitol) to initiate somatic embryo 
formation. Somatic embryos that proliferated CM4+ osmoticum were co-bombarded with the  
pAHC 20 and Ubi PLR plasmid by use of the particle flow gun. For each transformation event, 
50 mg of tungsten particles were sterilized in a 1.5 ml microcentrifuge tube with 500 µl of 95% 
ethanol for 20 minutes, washed five times with sterile water and resuspended in 500 µl of sterile 
de-ionized water. All transformation was co-bombarded with a pAHC 20 plasmid that encodes 
for herbicide resistance as a selectable marker. The ratio of DNA to selectable marker was 1:1. 
Plasmid DNA used prepared at a concentration of 1 µg/µl and a total of 5 µl of plasmid DNA 
was mixed with 25 µl of the re-suspended tungsten particles and allowed to incubate at room 
temperature for 1 minute. Next, plasmid DNA was precipitated onto tungsten particles by adding 
25 µl of 2.5 M CaCl2 and 10 µl of 100 mM spermidine and then incubated on ice for 4 minutes. 
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Following incubation, 50 µl of the supernatant was discarded and 15 µl of DNA-coated particles 
used for bombardment. For bombardment, 2 µl aliquot of DNA-coated particles was applied on a 
swinney filter holder which was secured to a leur-lock adapter located at the top of the PIG 
chamber. The arranged embryogenic clusters were covered with a 500 um mesh baffle and 
placed in the PIG chamber 15 cm below the filter holder. A vaccum of approximately 94 kPa 
was applied to the chamber and the DNA coated particles were propelled towards the target 
embryo with  60 pounds per square inch microburst of helium gas.  After transformation, 
transformed plants were selected through media containing herbicide of varying strength 
according to published protocols 
Sixteen hours (16) after co-bombardment, selection for transformed tissue was on CM4 
medium containing 5 mg l-1 glufosinate. Sub-culturing was done after 2 weeks to medium 
strength of 10 mg l-1 glufosinate. After 10-15 weeks, growing clumps transferred to shoot 
production medium, MSP containing MS with glufosinate selection until green shoots were 
observed. The cultures were then transferred to elongation and rooting medium (MSE) 
containing 5 mg l-1 glufosinate and cultured 2-3 weeks. Healthy looking plantlets obtained were 
transferred to soil and grown in environmentally green house. 
Leaf painting assay for confirmation of the selectable marker, bar 
To examine the expression of the selectable bar resistance gene in the transgenic plants, 
leaf painting was done as previously described. Leaves from each tiller to be tested were marked 
with a sharpie 2/3 from the leaf base. Using cotton as the brush, freshly prepared solution of 
herbicide, liberty (0.2% v/v) was applied on the topside of the leaf. Visual observations were 
recorded 7-10 days after painting and liberty sensitive tillers were clipped off. 
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Polymerase chain reactions (PCR) for the bar, PLR and Ubi PLR gene 
combination 
For all the three primer sets, PCR analysis was done with genomic DNA extracted from 
leaves of transgenic wheat plants using the phenol chloroform extraction method. To extract 
DNA, 100mg of leaf tissue was grinded in microcentrifuge tube or porcelain pots under liquid 
nitrogen. Grinded tissue was then subjected to the 500 ul of extraction buffer (Glycine-SDS) and 
500 ul phenol: choloform: IAA (25:24:1) and mixed on a vertical shaker. The extract was then 
centrifuged for 15 minutes at 4,000 x g and the supernatant subjected to second extraction with 
500ul chloroform: IAA (24:1). The second extract was mixed for 10 minutes, centrifuged at 4000 
x g and the supernatant transferred to a fresh tube. Sodium acetate (3 M), 1/10 volume and 
isopropanol, I volume of supernatant volume was then used to pellet the DNA. Pelleted DNA 
was washed in 70% ethanol and let dry at room temperature for 10-60 minutes. The pellet was 
subsequently dissolved in 10 mM Tris-HCI buffer under a water-bath set at 65 0C for 10 minutes. 
RNase (1.0 ul) was then added to the DNA sample and DNA amount determined through 
measuring absorbance at 260 nm with the nanodrop (Nanodrop Technologies, Wilmington, DE). 
To perform PCR, 100-500 ng of genomic DNA from transgenic plants was screened by primer 
sets; Bar AB F and Bar AB R, PLR F and PLR R, and Ubi PLR F and Ubi PLR R (Table 1) in a 
PTC-220 thermal Cycler (Hybaid Limited, Hastings, UK). Samples were denatured, annealed 
and extended at 940C, 58-60 0C, and 72 0C for 1 minute, 30 sec and 45 sec, respectively for 35 
cycles and a final extension at 72 0C . PCR products were visualized through 1.8% agarose gel 
electrophoresis. Positive transformants were subjected to southern blot analysis to confirm 
integration of the PLR gene 
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Southern blot analysis for detection of integration of the PLR gene 
Genomic DNA was isolated as described above, digested with a single enzyme cutter, 
Bam HI and separated by electrophoresis in 0.8% agarose (30V) over 14-24 hrs. At the same 
time, the probe to be used was obtained by restriction enzyme digestion of the pGem Teasy 
plasmid with EcoR 1 to obtain the 1.2 kb PLR gene probe. After electrophoresis, the gel was 
stained with fresh ethidium bromide (EtBr) for 10 minutes, rinsed in 2 volumes of double 
distilled H20 and depurinated with 2 volumes of 0.25N HCl until the bromophenol blue dye 
marker turned yellow. DNA in the gel was denatured twice with 0.4M NaOH for 10 minutes. A 
Hybond N+ membrane soaked in the same concentration of NaOH was used for DNA transfer by 
an alkaline transfer procedure according to manufacturer’s instructions (Amersham, Piscataway, 
NJ). Alkaline transfer was performed overnight at room temperature. To detect for introduced 
PLR DNA within the wheat genome, the nylon membrane was hybridized for 12-24 hrs with the 
1.2kb 32P-dCTP labeled F .intermedia PLR gene probe. After hybridization, the blotted 
membrane was washed in phosphate buffer solution containing 20% SDS for 20-40 minutes 
twice and again with the same phosphate buffer solution containing ¼ SDS amount of the first 
solution. The membrane was then exposed in a phosphor image cassette and developed using the 
Scan Quant software (Molecular Dynamics Inc., Sunnyvale, CA). 
Isolation of partial wheat PLR sequence 
Wheat genomic DNA was extracted as described above from non-transgenic wheat 
(cultivar ‘Fielder’). Primer sets (PLR F and PLR R) were used to PCR amplify the 539bp PLR 
fragment from wheat (same PCR conditions as above for PLR primers). The PCR products were 
purified using the montage DNA PCR purification kit (Millipore Corporation, Bedford, MA), 
inserted into the cloning site of the pGem Teasy vector (Promega, Madison, WI) through ligation 
 86
as described above. To increase plasmid DNA, bacterial transformation was performed using 
JM109 competent cells as described by manufacturer’s instructions (Promega, Madison, WI). 
Positive clones with the inserted PLR gene fragment from wheat were confirmed through PCR 
analysis with the PLR primers as described above and subjected to sequencing at the Kansas 
State University, gene sequencing facility with pGem Teasy primers (Promega, Madison, WI). 
The sequences obtained from the positive clones were then compared to Forsthysia PLR 
sequence by use of the  national centre for biotechnology sequence comparison software (NCBI).  
Relative real time PCR quantification of Ubi PLR expression in transgenic 
wheat lines 
To quantify for levels of F. intermedia PLR expression in different positive transgenic 
plants, total RNA was isolated from young leaf tissue by use of the total RNA isolation kit 
according to manufacturer’s instructions (Promega, Madison WI). Briefly, samples were 
homogenized with the RNA lysis buffer®, transferred to a fresh tube and RNA dilution buffer® 
added and centrifuged to obtain supernatant. The supernatant was mixed with 95% ethanol and 
transferred to a spin column containing cellulose for attachment of poly + (A) RNA. Dnase 
activity was stopped with the Dnase stop solution® and the column washed with the RNA wash 
solution® before elution with nuclease free water. Total RNA was then qualified by use of the 
nanodrop (Nanodrop Technologies, Wilmington, DE) through measuring UV absorption at 
260nm. The ratio of wavelength 230/260 was used to determine for RNA purity. First strand 
cDNA synthesis was performed using 1 µg of total RNA and random hexamer primers with 
AMV reverse transcriptase® according to manufacturer’s  conditions (Promega, Madison, WI). 
The samples were then diluted to an equivalent volume and an equivalent amount used for real 
time PCR analysis. The primer set, PLR RT F and the PLR RT R, (Table. 1) were used to 
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amplify a 99bp fragment of the F. intermedia PLR gene using the Sybr green PCR master-mix® 
(Bio-rad Laboratories, Hercules, CA). Real time PCR was performed according to manufacturers 
instructions with the PCR mastermix® in the iCycler thermal cycler (Bio-rad Laboratories, 
Hercules, CA). Ten to eighty pg of Ubi PLR was initially amplified to make sure that the 
efficiency of the F. intermedia PLR RT primers was 100%. PCR products from the cDNA were 
then qualified with the iCycler Bio-rad software (Bio-rad Laboratories, Hercules, CA). The 
experiment was repeated three times and the results plotted as relative quantification in log CT 
units.  
SDG identification and quantification in transgenic wheat seeds 
Sample extracts from transgenic wheat T2 seeds were quantified for SDG levels by 
HPLC analysis. Transgenic and non transgenic seeds (10-30) equivalent to 0.2-0.5 mg were 
ground using magic mill II (Nutrition life styles®, Gilmer, TX) and defatted using hexane before 
drying in the hood overnight. Flavone was added to the extraction solution (methanol: acetone: 
water, ratio 1:5:4) to make a final concentration of 5 mM. Extraction buffer was then added to 
defatted whole extracts which were homogenized for 2 minutes under cold conditions through 
addition of liquid nitrogen. The homogenate was subjected to centrifugation at 4000 x g for 15 
minutes and the supernatant obtained was kept under reducing conditions through passage of 
liquid nitrogen. SDG was then extracted with 3 diethyl ether extractions as in study 1. The 
residue obtained after evaporation of the diethyl ether was dissolved in 100% methanol and 
subjected to a HPLC and HPLC-MS/ESI protocol as described in study 1. Quantification was 
done by comparing peak area ratio of a known amount of commercial SDG run on the HPLC 
with the internal standard and the peak area ratio of the SDG obtained from individual 
transgenic/wild type wheat plant lignan extracts. 
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